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The role of palliative surgery in the management of acute complications in patients
with disseminated malignancy remains controversial given the complexity of assessing
acute surgical risk and long-term oncologic outcome. With the emergence of checkpoint
blockade immunotherapy, there appears to be an increasing role for historically
palliative procedures as a bridge to systemic immunotherapy. This is especially evident
in advanced microsatellite instability-high (MSI-H) colorectal cancer where malignant
obstruction and fistula formation are more common and where immunotherapy with
checkpoint blockade (anti-PD-1/PD-L1, anti-CTLA-4) has a high response rate with
potential for favorable oncologic outcomes. We present a series of three patients
with MSI-H metastatic colorectal cancer complicated by malignant bowel obstruction
and fistula formation, who having progressed on standard chemotherapy, underwent
palliative intervention as a bridge to immune checkpoint blockade with durable and
clinically meaningful anti-cancer responses. These cases highlight the need to re-evaluate
the role of historically palliative operations in the setting of disease progression for
immunotherapy-responsive tumors.
Keywords: palliative surgery, metastatic colorectal adenocarcinoma, microsatellite instability high (MSI-H),
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INTRODUCTION
Surgery as a component of palliative care in the setting of
metastatic colorectal cancer (mCRC) has been, and remains,
controversial due to a narrow risk/benefit ratio with the potential
for significant postoperative morbidity and mortality impacting
quality of life, performance status, and tolerability of additional
anti-cancer therapies (i.e., cytotoxic chemotherapy). The
decision to intervene surgically for patients with disseminated
malignancy continues to revolve around various challenging
medical and ethical considerations including disease burden,
trajectory of disease progression with and without systemic
therapy, availability of efficacious systemic treatment options,
and patients’ goals of care (1). Our previous work analyzing a
large statewide database indicated that compared to medical
management, surgical management of malignant bowel
obstructions was associated with increased complications,
increased in-hospital mortality, and lower rates of discharges
to home (2). This is made more difficult by the finding
that common risk stratification tools (American Society of
Anesthesiology classification, Charlson comorbidity index, and
modified frailty score), do not adequately predict postoperative
adverse events in this population (3). These considerations are
especially challenging for patients receiving chemotherapy, as
both invasive surgery and chemotherapy require fit patients with
good performance status to optimize the risk/benefit ratio of
multimodality therapy.
One subset of colorectal cancer patients where this risk/benefit
ratio is changing is in those with tumors exhibiting microsatellite
instability-high (MSI-H) genotypes—a marker of dysfunctional
DNA repair proteins, which can represent either somatic or
germline (i.e., Lynch Syndrome) mutations. Given the high
rate of response and durability of response with immune
checkpoint blockade in MSI-H (also known as mismatch repair
deficient (dMMR) when determined by IHC) colorectal cancer
patients (where a high tumor mutational burden leads to partial
and complete responses in ∼30–50% of patients), palliative
interventions may alleviate acute surgical processes, and rather
than strictly improving quality of live, can act as a bridge to
immunotherapy with the potential for prolonged survival.
The most common palliative surgical intervention in
advanced colorectal cancer remains stoma creation for relieving
malignant bowel obstruction and its associated symptoms.
Ostomy creation does not provide a cancer-related survival
benefit, but does provide symptom relief and can improve quality
of life (4). The role of other invasive surgical procedures in the
setting of malignant bowel obstruction remains controversial. A
Cochrane review investigating the efficacy of surgery for bowel
obstruction in advanced cancers was published in 2016 (5). This
analysis of 43 studies, including 4,265 patients, found a wide
distribution of results, with 26.7 to 68% of patients obtaining
clinical resolution of symptoms after surgery. More so, rates of
re-obstruction ranged from 0 to 63%, but data on the time to
re-obstruction was limited. The authors of this large analysis
concluded that the data are too limited to make any conclusions
on surgical management recommendations (5). A separate
analysis evaluating the literature on type of palliative surgery for
obstruction in patients with peritoneal carcinomatosis found
an overall survival (OS) of 6.4 months after palliative surgery.
On subset analysis, patients who underwent tumor resection
had an OS of 7.2 months and those that underwent enteral
bypass had an OS of 2.7 months (6). These analyses included
studies evaluating a heterogenous cohort of colorectal cancer
patients, which included both microsatellite stable (MSS) and
MSI-H tumor types. These studies also preceded the era of
immunotherapy where patients with MSI-H/MMR deficient
pathogenesis can have significant responses to checkpoint
blockade therapy. Given these findings, there is likely greater
utility for palliative surgery in MSI-H colorectal cancer patients
given the potential for durable responses and prolonged survival
benefits with immunotherapy.
MSI-H tumors represent about 5% of mCRC cases and are
associated with a poor prognosis in comparison to MSS tumors
(7, 8). These tumors tend to invade deeper and are poorly
differentiated on histology (9, 10). In the pre-immunotherapy
era, recurrent MSI-H disease also carried worse OS from
diagnosis to death (HR: 1.363, P = 0.035) as well as OS
from recurrence to death (HR: 2.667, P < 0.001) compared
to MSS disease (11, 12). Profound and durable responses
with immunotherapy, however, has changed the expected OS
of MSI-H CRC patients. Le et al. demonstrated in a phase
II study that MSI-H/dMMR mCRC patients who received
pembrolizumab (anti-PD-1) achieved a 90% disease control
rate, 78% immune-related progression-free survival (PFS) at
20 weeks, and an objective response rate of 30–40% (13).
Nivolumab (anti-PD-1) has also shown clinical benefit [overall
response rate (ORR), 31%; disease control rate, 69%; 12 month
OS, 73%] in previously treated patients with MSI-H/dMMR
mCRC (14). Dual agent checkpoint blockade therapy also
appears promising in MSI-H/dMMR disease as a recent cohort
analysis from the CheckMate-142 trial who were treated with
nivolumab/ipilimumab (anti-PD-1 with anti-CTLA-4) showed
an ORR of 55%, 12 week disease control rate of 80%, PFS rate
of 71% and OS of 85% after 1 year (15). Notably, there was a 3%
complete response (CR) rate with combination therapy.
While reported response rates are promising, some critical
factors limit the efficacy of this treatment. Currently, checkpoint
blockade therapy is not an approved first-line agent in
mCRC, therefore, patients presenting with acute complications
after progressing on cytotoxic therapy require more durable
interventions if they are to start immunotherapy. Additionally,
unlike traditional cytotoxic therapies, time to response to
immunotherapy can be longer. In recent clinical trials, for
example, the median time to response for both nivolumab
and nivolumab/ipilimumab was 2.8 months, and was 4.8
months for pembrolizumab (13, 14). This creates the scenario
where patients must first fail standard chemotherapy before
starting immunotherapy, and once on immunotherapy, a
clinical benefit may not be determined for weeks to months.
The challenge in this patient population is that without a
more durable surgical intervention for acute complications of
mCRC, MSI-H patients may miss the opportunity to start
and maintain potentially life-prolonging therapies. Given the
dramatic clinical improvements with novel immunotherapeutics,
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surgical intervention for complications secondary toMSI-HCRC
should be considered as a bridge to immunotherapy in select
patients, and not strictly for the relief of obstructive symptoms.
To this end we present three patients with MSI-H
mCRC who developed bowel obstructions or fistulae
related to their malignancy while on chemotherapy. After
significant deliberation with each patient and multidisciplinary
treatment planning, two patients underwent palliative surgical
interventions and one underwent an interventional radiology-
based procedure with the intention of acting as a bridge to
immunotherapy. These interventions allowed patients to receive
and benefit from immunotherapy with durable disease control.
Pertinent patient demographic and medical history details are
provided in Supplementary Table 1 and the timeline of events is
shown in Figure 1.
CASE DESCRIPTION
Case 1
A 33 year-old woman presented with abdominal pain in
2018. Computed tomography (CT) imaging revealed a 3.9 ×
3.7 cm heterogenous soft tissue mass in the ascending colon
near the hepatic flexure with invasion of the right anterior
pararenal fascia and the second/third portion of the duodenum.
There were associated enlarged and necrotic portacaval and
mesenteric lymph nodes and a 1 cm hypodense lesion in the right
hepatic lobe. Colonoscopy with biopsy confirmed a diagnosis
of adenocarcinoma, and subsequent immunohistochemistry
(IHC) showed loss of MLH1 and PMS2 gene expression
consistent with MSI-H/dMMR. The patient was started on
5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), but
continued experiencing symptoms of partial bowel obstruction
including severe nausea, emesis, abdominal pain and dizziness
from hypovolemia. CT imaging at this time is shown in
Figure 2A. Given no evidence of response to chemotherapy for
2 months, she was transitioned to pembrolizumab (anti-PD-
1). Shortly after initiation of pembrolizumab, she developed a
partial large bowel obstruction secondary to the tumor. This was
relieved by placement of a percutaneous gastrostomy tube and
she was started on total parenteral nutrition (TPN) and resumed
immunotherapy. Following three cycles of immunotherapy,
imaging was consistent with partial response in the primary
tumor and associated lymph nodes and the patient was
also able to transition to an oral diet. However, after 8
months on immunotherapy she developed complete bowel
obstruction, though imaging showed continued response in
the primary tumor and metastases. The bowel obstruction was
thought to be from adhesions and inflammatory changes and
not progression of the patient’s primary disease. Following
multidisciplinary discussions between the patient and her
treatment team including Medical Oncology, Surgical Oncology,
and Palliative Care, the decision was made to proceed with
FIGURE 1 | Timeline of events in the care of each patient with MSI-H metastatic colorectal cancer. Timeline demonstrates the variable response to therapy before and
after palliative surgery. Palliative surgical interventions are indicated in red, demonstrating the relationship to initiation of immunotherapy and the sustained duration of
response.
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FIGURE 2 | Changes in tumor or metastasis size by computed tomography (CT) imaging before and after initiation of checkpoint blockade immunotherapy.
Representative imaging showing decrease in size of colon mass for patient #1 (A,B) and liver metastasis for patient #2 (C,D) and patient #3 (E,F).
surgical intervention. She underwent an internal colonic bypass
with anastomosis of the cecum to the transverse colon bypassing
the inflamed segment. She recovered without complications
and was able to resume oral alimentation with resumption of
pembrolizumab monotherapy. At the time of this report, 14
months since initiating pembrolizumab, imaging demonstrates
continued partial response on immunotherapy (Figure 2B).
Case 2
A 62 year-old man with a history of liver transplantation
for alcoholic cirrhosis underwent screening colonoscopy and
was found to have moderately differentiated adenocarcinoma
of the ascending colon. Molecular analysis identified loss of
MLH1 and PMS2 genes, consistent with MSI-H/dMMR disease.
The patient initially underwent a right hemicolectomy, and
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surgical pathology revealed AJCC stage IIIc (pT3N2b) disease
with 7 of 27 lymph nodes positive for adenocarcinoma. He
was treated with adjuvant FOLFOX, and in the following
6 months developed hepatic metastases along with diffuse
omental and mesenteric disease consistent with failure of
first-line therapy (Figure 2C). Additional chemotherapeutic
regimens did not produce any response, and he subsequently
developed a complete small bowel obstruction and acutely
worsening cachexia.
In the setting of concurrent liver dysfunction, prior
liver transplantation, and new extensive liver metastases,
discussions regarding surgical intervention vs. a less invasive
percutaneous option were debated. With the potential to
receive immunotherapy and given the increased risk associated
with this unique patient, an interventional radiology-guided
percutaneous gastrostomy tube was placed to palliate his
obstructive symptoms, and he initiated TPN for caloric
support. After extensive discussions regarding the unique
risks of immunotherapy in the setting of liver transplantation,
the patient was started on pembrolizumab. On-treatment
follow-up imaging showed a partial response of both
the primary and metastatic lesions (Figure 2D) and the
patient experienced clinical improvement in his obstructive
symptoms after 2 months of therapy. He resumed oral
intake with cessation of TPN and continues to receive
benefit on pembrolizumab several months later, without
any subsequent obstructive episodes. While the risk of
undergoing a palliative surgery was felt to be too high in
this specific patient, this case highlights the unique risk/benefit
profile that must be evaluated in this increasingly complex
patient population.
Case 3
The final case is a 37 year-old man who initially experienced
persistent alternating diarrhea and constipation. Within 5
months, these symptoms progressed to urinary retention,
and imaging revealed a 5.5 cm sigmoid mass with invasion
into the bladder and metastatic liver lesions (Figure 2E).
Image-guided percutaneous liver biopsy confirmed metastatic
adenocarcinoma from a colon primary. Molecular analysis
confirmed MSI-H/dMMR disease, and he was started
on 5-fluorouracil, oxaliplatin, leucovorin, and irinotecan
(FOLFOXIRI) chemotherapy. Within 2 months of starting
chemotherapy he developed a colovesicular fistula, thus limiting
his ability to receive and tolerate further chemotherapy.
Multidisciplinary discussions were held between colorectal
surgery, urology and medical oncology, and it was determined
that resection would offer the best chance for managing
the fistula, controlling ongoing infections, and resuming
cancer-directed therapy. He subsequently underwent an en
bloc resection of the sigmoid colon and dome of the urinary
bladder with formation of an end colostomy. Following an
uncomplicated postoperative recovery, he was started on dual
checkpoint blockade, nivolumab (anti-PD-1) and ipilimumab
(anti-CTLA-4), with a partial response of the liver metastases
(Figure 2F). The patient has continued to benefit from
durable response from immunotherapy and has since returned
to work.
DISCUSSION
The three cases presented here highlight the changing landscape
of oncology care in the era of immunotherapy for colorectal
cancer patients with MSI-H disease and a reasonable expectation
of response to immune checkpoint blockade. For those who
respond to treatment, advanced MSI-H disease now carries
a much different prognosis compared to the pre-checkpoint
blockade era. This is dramatically changing the decision-making
and management of medical and surgical specialists who provide
care to these advanced cancer patients.
In colorectal cancer, checkpoint inhibitors such as
pembrolizumab, nivolumab, and ipilimumab have been
approved for MSI-H/dMMR metastatic colorectal cancer that
has failed standard therapies (13–17). While studies on the
benefits of palliative surgical interventions in the setting of
malignant obstruction and fistula formation may have only
suggested modest improvement in overall survival at best, these
interventions were often followed by conventional chemotherapy
or best supportive care in non-selected patients. With immune
checkpoint inhibitors there appears to be a more significant
survival benefit from palliative interventions, including surgery,
as a bridge to these specific therapies. The response rates are
variable but many patients, such as the ones described here, have
had significant and lasting responses. Furthermore, it does not
appear that age had a significant impact on response as the trials
included patients aged 20–80 years.
Since checkpoint blockade immunotherapeutics are not yet
approved for first-line therapy, there is often a significant period
on traditional chemotherapy before starting immunotherapy.
In the CheckMate-142 trial, 54% of patients had received 3 or
more chemotherapy regimens before starting immunotherapy
on trial (14). Given the aggressive disease in MSI-H colorectal
cancer in addition to its well-known resistance to chemotherapy,
patients may present with acute complications or develop
bowel obstruction and fistulae during chemotherapy. Another
consideration when evaluating these patients for surgical
procedures is the adverse effects of therapy and the impact of
immunotherapeutics on the safety of surgery. Regarding adverse
events, immune-related adverse events (IRAEs) are common
with anti-PD-1 and anti-CTLA-4 therapy and patients should
be monitored for after initiation of therapy. Common IRAEs
include, but are not limited to, colitis, enteritis, pneumonitis
and hepatitis. The risk of IRAEs should be determined in a
patient-specific manner, and increased risk should not preclude
initiation of checkpoint blockade therapy (18). As for surgical
complications, a smaller, retrospective study from the Mayo
Clinic, Florida was recently published with results of their
experience to help answer this question (19). Elias et al. identified
17 patients who underwent 22 unique operations while on
perioperative immunotherapy. Although their patient cohort
did not include any patients with colorectal malignancies,
the authors report five bowel operations with seven bowel
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anastomoses and no post-operative anastomotic leaks. Elias
et al. along with another study examining the safety of
perioperative ipilimumab in metastatic melanoma (20), suggest
that perioperative immunotherapeutics do not present a distinct
contraindication to surgery when indicated.
Our recent experience suggests that interventions that are
historically viewed as “palliative” should be re-evaluated and
thoughtful consideration be given for surgical interventions as a
bridge to immunotherapy in select metastatic colorectal cancer
patients withMSI-H disease. BecauseMSI-H disease is frequently
less responsive to standard chemotherapy, intervening for
complications such as bowel obstruction and fistulae formation
may be more appropriate as this allows for palliation of
symptoms and for patients to transition to checkpoint blockade
therapy, where response rates are more pronounced. Our
experience described in this study is limited by a small sample
size and has potential for selection bias. Therefore, the criteria
for patient selection, route and timing of intervention requires
investigation and should be discussed in a multidisciplinary
setting. Further investigation is warranted in this subset of MSI-
H mCRC patients to validate the role of palliative interventions
that may provide a window for immunotherapy, potentially
leading to prolonged and durable responses in this unique
patient population.
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